FDA Inspection 1251795 — BioMarin Pharmaceutical, Inc.
The FDA completed an inspection of BioMarin Pharmaceutical, Inc. on August 19, 2024 in Novato, CA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- August 19, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Novato, CA (United States)